GENSCRIPT BIO (01548) has released its interim results for the six months ended June 30, 2026, reporting a 27.35% increase in revenue to $404 million. The company's loss attributable to equity holders narrowed by 29.25% to $129 million, with a loss per share of 5.92 cents.

The revenue growth was driven by three key factors. First, rising industry demand for AI-driven drug discovery and antibody drug discovery accelerated the "gene-to-protein" business expansion. Second, a strong recovery in upstream demand within the CRDMO sector boosted project intake and capacity utilization rates. Third, continued expansion in the industrial enzyme business contributed to steady sales growth during the reporting period.